Milford, PA -- (ReleaseWire) -- 05/05/2016 --CEO of Manzo Pharmaceuticals (OTCPink:MNZO) and creator of patented Lacto-Freedom probiotic, Kenneth Manzo, recently visited their manufacturer's GMP and FDA approved probiotic plant in the USA and expressed his great satisfaction with the manufacturer and their professionalism.

Shortly after the confirmation of the deal between Manzo Pharmaceuticals and their new manufacturing partners, Ken Manzo – CEO Manzo Pharmaceuticals - visited the plant and took a detailed tour to understand the working processes and the facilities available. Afterwards, he expressed his immense satisfaction with the plant and the professionalism shown by people there.

"I was very impressed and pleased with their manufacturing plant and professionalism. They are a major USA based probiotic producer and supplier, and their professionalism and facilities prove why that is so. I am glad we are working together on this deal", said Ken Manzo.

Reportedly, samples of their Lacto-Freedom probiotic were sent to the manufacturing facility to test and produce. Working on the samples received, the manufacturers have already started testing and reproducing it so they are one step closer to making it available on the market.

"The manufacturers have made sure that they come up with the testing and production at the highest possible level and thereby making sure that the end product is the best which people can get", the CEO stated.

The visit of the manufacturing facility by Ken Manzo showed his concern and active participation in the whole process, starting from creating this unique and revolutionary probiotic, getting it patented, finalizing a deal with one of the major manufacturers of probiotics and is now producing the probiotic. With the probiotic under production, people with Lactose Intolerance will not have to wait very long to have lactose containing products without discomfort.

About Manzo Pharmaceuticals, Inc.
Manzo Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the research, development, and testing of patented and non-patented solutions and remedies. Most notable is a patented probiotic for lactose intolerance, and a natural sleep aid.

For more information follow the company on twitter at @manzopharma, and visit www.manzopharma.com.

DISCLAIMER:
This Press Release may contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The Company has tried, whenever possible, to identify these forward-looking statements using words such as "anticipates," "believes," "estimates," "expects," "plans," "intends," "potential" and similar expressions. These statements reflect the Company's current beliefs and are based upon information currently available to it. Accordingly, such forward-looking statements involve known and unknown risks, uncertainties and other factors which could cause the Company's actual results, performance or achievements to differ materially from those expressed in or implied by such statements. The Company undertakes no obligation to update or advise in the event of any change, addition or alteration to the information catered in this Press Release including such forward-looking statements.

Contact:
Manzo Pharmaceuticals Inc.
570-249-6000
manzopharma@outlook.com

Source: UPTICK Newswire